Lara Sullivan - Mar 31, 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Stock symbol
PYXS
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:15 PM
Previous filing
Oct 7, 2021
Next filing
Apr 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +743K +248.53% $0.00 1.04M Mar 31, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.